EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
3.4.24.29 | alpha2-Macroglobulin | a regulatory serpin, the initial N-terminal hydrolysis of alpha2-macroglobulin by aureolysin does not affect the serpin inhibitory activity, cleavage within its exposed reactive loop is associated with a decreased inhibitory activity, down to 23% of the control inhibitor | Staphylococcus aureus | |
3.4.24.29 | EDTA | - |
Staphylococcus aureus | |
3.4.24.29 | plasminogen activator inhibitor-1 | PAI-1, a regulatory serpin, interaction analysis with aureolysin, overview, the proteolytic degradation of PAI-1 by aureolysin is associated with a drastic decrease in its capacity to inhibit uPA, down to 7% of the inhibitory activity of the control PAI-1 | Staphylococcus aureus |
EC Number | KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|---|
3.4.24.29 | additional information | - |
additional information | kinetics | Staphylococcus aureus |
EC Number | Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|---|
3.4.24.29 | extracellular | aureolysin is secreted | Staphylococcus aureus | - |
- |
EC Number | Metals/Ions | Comment | Organism | Structure |
---|---|---|---|---|
3.4.24.29 | Ca2+ | - |
Staphylococcus aureus |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.4.24.29 | Staphylococcus aureus | - |
wild-type strains 8325-4 and Newman, and clinical isolates | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.4.24.29 | alpha2-macroglobulin + H2O | processing of the inhibitor, the initial N-terminal hydrolysis of alpha2-macroglobulin by aureolysin does not affect the serpin inhibitory activity, cleavage within its exposed reactive loop is associated with a decreased inhibitory activity, down to 23% of the control inhibitor | Staphylococcus aureus | ? | - |
? | |
3.4.24.29 | Gelatin + H2O | - |
Staphylococcus aureus | ? | - |
? | |
3.4.24.29 | plasminogen + H2O | - |
Staphylococcus aureus | angiostatin + mini-plasminogen | - |
? | |
3.4.24.29 | plasminogen activator inhibitor-1 + H2O | processing of the inhibitor, the proteolytic degradation of PAI-1 by aureolysin is associated with a drastic decrease in its capacity to inhibit uPA, down to 7% of the inhibitory activity of the control PAI-1 | Staphylococcus aureus | ? | - |
? | |
3.4.24.29 | pro-urokinase-type plasmin activator + H2O | human substrate, activation by cleavage into two enzyme chains, activity by wild-type strains 8325-4 and Newman, and clinical isolates, overview, no activity with N-terminal enzyme substrate mutants, overview | Staphylococcus aureus | 2 chains of urokinase-type plasmin activator | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
3.4.24.29 | Aur | - |
Staphylococcus aureus |
EC Number | Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|---|
3.4.24.29 | 37 | - |
assay at | Staphylococcus aureus |
EC Number | pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|---|
3.4.24.29 | 7.4 | 7.8 | assay at | Staphylococcus aureus |